MOBIDIAG-LTD.
9.10.2019 08:02:12 CEST | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the CE-IVD marking of the Novodiag® Stool Parasites test, a comprehensive and cost-effective molecular diagnostic test for the detection of intestinal parasites directly from stool samples.
Tuomas Tenkanen, CEO of Mobidiag, said, “Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labor-intensive and require a high level of skill. Our Novodiag® Stool Parasites test is the only fully automated, rapid, cost-effective and easy to use diagnostic solution that can identify a comprehensive range of parasitic targets, for use in laboratories and hospitals.”
“Novodiag® Stool Parasites is the fourth test on our Novodiag® platform and, together with our Novodiag® C. difficile , Novodiag® Bacterial GE+ and Novodiag® CarbaR+ tests, further strengthens our offering in the detection of gastrointestinal infections. With our complementary Amplidiag® and Novodiag® solutions, we continue to offer a range of highly versatile combined solutions enabling the broad application of molecular diagnostics around the world.”
Novodiag® Stool Parasites combines real-time PCR and microarray technologies to allow cost-effective, rapid and comprehensive detection of >95% of intestinal parasites. This syndromic test is designed to run on-demand using the automated Novodiag® system and is able to detect the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. The test provides complete results in 90 minutes with less than five minutes hands-on time by an operator.
While most infections and death from parasitic diseases affect people in developing countries, increasing incidence in developed nations combined with a shortage of microscopy trained hospital staff are driving demand for this test.
The Novodiag® Stool Parasites test is now available directly through Mobidiag and local distributors. For more information, visit https://mobidiag.com/products/novodiag/#stoolparasites
About Novodiag®
Stool Parasites
Novodiag®
Stool Parasites is an automated qualitative nucleic acid-based diagnostic test for detecting the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. It is part of the Novodiag®
platform, Mobidiag’s fully automated molecular testing platform for diagnostics of infectious diseases and antibiotic resistances. Combining real-time PCR and microarray technologies, Novodiag®
platform allows direct analysis of a patient sample placed in a disposable cartridge for comprehensive screening of multiple or single pathogens. In addition of Novodiag®
C. difficile
, Novodiag®
Bacterial GE+ and Novodiag®
CarbaR+, we launch a new test, the Novodiag®
Stool Parasites which complements our offer for gastrointestinal infections. Our panel covers >95% of stool parasites.
About Mobidiag Ltd.
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adaptability for large scale manufacturing, Mobidiag’s Amplidiag®
and Novodiag®
platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s intial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.
Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005570/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom